Lundbeck and Otsuka announce positive results

Following the positive results showing reduced agitation in patients with Alzheimer’s dementia treated with brexpiprazole, Lundbeck hosted a conference call and webcast for investors and analysts on June 27 at 10:00 AM CEST to briefly discuss the topline results of the trial. 

 

Watch the replay of the webcast here

Download presentation

This is Lundbeck

We are one of the only pharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization. 

About Us

With more than 70 years of neuroscience expertise, Lundbeck has developed and commercialized some of the world's most widely prescribed therapies for brain diseases.

Our Science

LATEST NEWS

See All News

Come join us in making a difference to patients worldwide.

Job Opportunities

Explore the latest financial developments at Lundbeck.

Investors

a better life for people with brain diseases

At Lundbeck, we see patients as people and are committed to support the person behind the disease. 

Patients

Partnering

The complexity of brain diseases requires a concerted effort. We are committed to develop new and better treatment options from innovations born in house or externally.

Read More
jason F. houston on working at Lundbeck

Advocacy Makes the Difference

Read More
See All Stories

Lundbeck at a glance

100

countries where our products are sold

5,300

employees supporting our purpose

1915

year Lundbeck was founded